Tremfya ^*

Tremfya (generic name: guselkumab) is a biologic medication used for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults. As an interleukin-23 (IL-23) inhibitor, guselkumab works by targeting and inhibiting the IL-23 cytokine, which plays a key role in inflammatory processes. By reducing the activity of IL-23, Tremfya helps alleviate the symptoms associated with these autoimmune conditions, such as skin lesions and joint inflammation. This medication offers a targeted approach to therapy with the aim of improving patient outcomes and quality of life. Tremfya is approved for patients who are candidates for systemic therapy or phototherapy for plaque psoriasis. For psoriatic arthritis, it may be used as monotherapy or in combination with other disease-modifying antirheumatic drugs (DMARDs). Its clinical benefits include clear or nearly clear skin in many patients with psoriasis and significant improvement in joint-related symptoms in psoriatic arthritis. Get more about Tremfya and its approved uses from this source.

Dosage

The recommended dose for both Plaque Psoriasis and  Psoriatic Arthritis is 100 mg, administered subcutaneously at weeks 0 and 4, and every 8 weeks thereafter. If a dose is missed, consult a healthcare provider to determine the next steps. Tremfya is administered as a subcutaneous injection. Patients or caregivers should be trained in proper injection techniques and advised to avoid injecting into areas of active psoriasis.

Storage

Store Tremfya in a refrigerator at 2-8°C (36-46°F). Keep the medication in its original carton to protect it from light. Do not freeze the medication or expose it to extreme temperatures. If there are questions, consult our blog on safe medicine management.

Common Questions About Tremfya

How does guselkumab work?

Guselkumab blocks IL-23, reducing inflammation and immune response associated with psoriasis and arthritis.

What is plaque psoriasis?

It is a chronic skin condition marked by red, scaly patches, often accompanied by itching.

What is an IL-23 inhibitor?

IL-23 inhibitors are biologics that target interleukin-23, a protein driving inflammatory responses.